Santiago RamÃ³n-GarcÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6453407/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme. International Journal of Molecular Sciences, 2022, 23, 771.	4.1	10
2	Comparison of 8Âweeks standard treatment (rifampicin plus clarithromycin) vs. 4Âweeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the) Tj ETQq0 0 0 rg 23, .	BT /Qverloc	k 19 Tf 50 702
3	Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria. Antibiotics, 2021, 10, 381.	3.7	10
4	lvermectin and COVID-19: Keeping Rigor in Times of Urgency. American Journal of Tropical Medicine and Hygiene, 2020, 102, 1156-1157.	1.4	138
5	The FICI paradigm: Correcting flaws in antimicrobial in vitro synergy screens at their inception. Biochemical Pharmacology, 2019, 163, 299-307.	4.4	33
6	Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening. PLoS Neglected Tropical Diseases, 2019, 13, e0007126.	3.0	12
7	Repurposing clinically approved cephalosporins for tuberculosis therapy. Scientific Reports, 2016, 6, 34293.	3.3	66
8	Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment. PLoS Neglected Tropical Diseases, 2015, 9, e0003996.	3.0	19
9	The mycobacterial P55 efflux pump is required for optimal growth on cholesterol. Virulence, 2015, 6, 444-448.	4.4	8
10	Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependentauthors' response. Journal of Antimicrobial Chemotherapy, 2014, 69, 1725-1726.	3.0	0
11	Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent. Journal of Antimicrobial Chemotherapy, 2014, 69, 1723-1724.	3.0	4
12	Challenges faced by multidisplinary new investigators on addressing grand challenges in global health. Globalization and Health, 2014, 10, 27.	4.9	4
13	Anthelmintic Avermectins Kill Mycobacterium tuberculosis, Including Multidrug-Resistant Clinical Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 1040-1046.	3.2	114
14	Targeting Mycobacterium tuberculosis and Other Microbial Pathogens Using Improved Synthetic Antibacterial Peptides. Antimicrobial Agents and Chemotherapy, 2013, 57, 2295-2303.	3.2	72
15	WhiB7, an Fe-S-dependent Transcription Factor That Activates Species-specific Repertoires of Drug Resistance Determinants in Actinobacteria. Journal of Biological Chemistry, 2013, 288, 34514-34528.	3.4	49
16	WhiB7, a transcriptional activator that coordinates physiology with intrinsic drug resistance in <i>Mycobacterium tuberculosis</i> . Expert Review of Anti-Infective Therapy, 2012, 10, 1037-1047.	4.4	47
17	Functional and Genetic Characterization of the Tap Efflux Pump in Mycobacterium bovis BCG. Antimicrobial Agents and Chemotherapy, 2012, 56, 2074-2083.	3.2	63
18	Ramariolides A–D, Antimycobacterial Butenolides Isolated from the MushroomRamaria cystidiophora. Journal of Natural Products, 2012, 75, 2178-2182.	3.0	45

SANTIAGO RAMÃ³N-GARCÃA

#	Article	IF	CITATIONS
19	The Mycobacterial Transcriptional Regulator whiB7 Gene Links Redox Homeostasis and Intrinsic Antibiotic Resistance. Journal of Biological Chemistry, 2012, 287, 299-310.	3.4	106
20	Synergistic Drug Combinations for Tuberculosis Therapy Identified by a Novel High-Throughput Screen. Antimicrobial Agents and Chemotherapy, 2011, 55, 3861-3869.	3.2	150
21	The Use of Popular Fiction to Present a Professional Scientific Career to High School Students. Journal of Microbiology and Biology Education, 2010, 11, 166-167.	1.0	Ο
22	Role of the <i>Mycobacterium tuberculosis</i> P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth. Antimicrobial Agents and Chemotherapy, 2009, 53, 3675-3682.	3.2	116
23	One-step isolation of plasma membrane proteins using magnetic beads with immobilized concanavalin A. Protein Expression and Purification, 2008, 62, 223-229.	1.3	46
24	Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG. Journal of Antimicrobial Chemotherapy, 2007, 59, 544-547.	3.0	51
25	Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. Journal of Antimicrobial Chemotherapy, 2006, 57, 252-259.	3.0	65
26	Novel Streptomycin Resistance Gene from Mycobacterium fortuitum. Antimicrobial Agents and Chemotherapy, 2006, 50, 3920-3922.	3.2	29